Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]-B7H3-BCH
- Development stage
- Unknown
- Lead developer
- Peking University Cancer Hospital & Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
[68Ga]-B7H3-BCH (also known as [68Ga]Ga-B7H3-BCH) is a gallium-68 labeled, B7-H3 (CD276)-targeted affibody-based radiotracer developed by Peking University Cancer Hospital (Beijing Cancer Hospital). It is designed for positron emission tomography (PET) imaging to non-invasively and quantitatively map B7-H3 expression throughout the body. B7-H3 is an immune checkpoint molecule overexpressed in multiple solid tumors, including osteosarcoma, breast cancer, lung cancer, and gastric cancer, while showing low expression in normal tissues. The tracer utilizes an optimized B7-H3-targeting affibody conjugated to a chelator (such as RESCA or NOTA) and radiolabeled with gallium-68, enabling high-affinity binding and rapid clearance for high-contrast tumor visualization. It is being evaluated in clinical trials for tumor-specific diagnostics, staging, and screening of B7-H3-targeted therapies.
- Other names
- B7H3 Affibody-BCHB-7H3 Affibody-BCHB 7H3 Affibody-BCH[68Ga]Ga-B7H3-NOTA
02
Targets
B7-H3
Beyond the preview
Go deeper on [68Ga]-B7H3-BCH.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on [68Ga]-B7H3-BCH.